Showing 1 - 1 results of 1 for search 'Bertrand Tehard', query time: 0.01s Refine Results
  1. 1
    Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.

    Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France. by Marine Sivignon, Rémi Monnier, Bertrand Tehard, Stéphane Roze

    Published 2020-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: